Spotlight on Multiple Sclerosis

Spotlight on Multiple Sclerosis

As MS drugs continue to make headlines, MedImpact’s Annual Trend Report offers insights on trends

As the number of people suffering from progressive, relapsing multiple sclerosis (MS) increases worldwide, a robust pipeline of MS agents potentially offers novel life-changing treatment options.

Multiple sclerosis is a chronic, unpredictable and often disabling autoimmune disease of the central nervous system that disrupts the flow of information between the brain and the body. The Multiple Sclerosis Foundation reports that number of patients with MS is increasing and currently estimates more than 2.5 million worldwide have MS — including 8,000 to 10,000 American children and adolescents. In fact, MS is the most common causes of neurological disability in young adults.

The recent FDA approval of Gilenya (fingolimod) marks the first approved drug to treat relapsing MS in pediatric patients. The approval of Gilenya represents a key advance in the care of pediatric patients ages 10 and older with MS.

MedImpact Industry Insights: Gilenya and Other MS Trends

MedImpact’s Annual Trend Report revealed that three out of the Top 10 Commercial Specialty Drugs were MS therapies in 2017. Multi-billion dollar blockbuster orphan drug Copaxone, a widely used injectable MS treatment, ranked third, followed by Tecfidera fourth and Gilenya at eighth.

As reported in our Annual Trend Report, drugs competing with Gilenya have been delayed and may not reach market until late 2018 or even 2019. The market expects other generics for Copaxone 40mg/mL in 2018, which will likely further erode branded market share. For additional trend insights on MS and other top therapeutic classes, download our 2017 Annual Trend Report.

Multiple sclerosis ranked third — following inflammatory disease and diabetes respectively— in the Top Therapeutic Classes in MedImpact’s commercial line of business. MS ranked ninth in Medicare but did not appear in the Top 10 Therapeutic Classes in Medicaid.

Check MedConnect regularly for highlights from our Annual Trend Report and to see how our drug data and annual trend insights compare with the latest drug trend and industry news.

  • Email